From Medscape Oncology

Medscape Medical News from the:

American Society of Hematology (ASH) 54th Annual Meeting

December 08 - 11, 2012; Atlanta, Georgia

This coverage is not sanctioned by, nor a part of, the American Society of Hematology.

Meeting Highlights at a Glance

Top News From ASH 2012: Slideshow
Highlights include that chemo is not necessary for APL, the debate about platelet transfusions in patients with hematologic malignancies is still unresolved, and quizartinib has unprecedented activity in relapsed AML.

Commentaries

BTK Inhibitors Open Door to Lymphoma Cure
Dr. Bruce Cheson reports on a plethora of data presented at ASH 2012 that heralds what he considers a new era in lymphoma management, one in which a cure may be in sight.

BRIGHT Not So Clear on Lymphoma Choice
The BRIGHT study presented at ASH 2012 showed R-bendamustine to be noninferior to R-CHOP, but what role each regimen plays in lymphoma management is still unclear, says Dr. Bruce Cheson.

Conference News

Medscape Oncology©  WebMD, LLC

Medscape Oncology Insights

BRIGHT Shines Light on R-Bendamustine in Lymphoma
Bruce D. Cheson, MD;
Ian W. Flinn, MD, PhD

Limit Therapy to Cure Limited-Stage HL?
Bruce D. Cheson, MD;
John A. Radford, MD

'R-Squared' Rates 98% Response in Lymphoma Patients
Bruce D. Cheson, MD;
Nathan H. Fowler, MD

New Lymphoma Drugs Send Chemo Packing
Bruce D. Cheson, MD;
Myron S. Czuczman, MD

Pre-Meeting Expert Commentary

ASH 2012: More Fuel for the Fire
Bruce D. Cheson, MD